HDAC9 and prostate cancer: In a mouse model of prostate cancer, pioglitazone significantly reduces the occurrence of bone metastasis at the clinically achievable dose of 30 mg/kg/day in synergy with the histone deacetylase (HDAC) inhibitor valproic acid.